3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
asciminib
15
Cyclophosphamide
12
fludarabine phosphate
10
Mycophenolic Acid
9
fludarabine
8
nilotinib
7
Whole-Body Irradiation
7
Imatinib Mesylate
6
Dasatinib
6
Tacrolimus
5
Sirolimus
5
Cyclosporine
5
venetoclax
4
bosutinib
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
ponatinib
3
Thiotepa
3
Stem Cell Transplantation
3
Peripheral Blood Stem Cell Transplantation
3
Cyclosporins
3
Busulfan
3
thymoglobulin
2
ruxolitinib
2
Specimen Handling
2
Mesna
2
Magnetic Resonance Spectroscopy
2
Filgrastim
2
Blood Component Removal
2
treosulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Everolimus
×
90 days
×
Clear all
No trials found.